Company Filing History:
4 out of 86 
1 out of 1,179 
Years Active: 2010-2021
Title: Kenneth Loveday: Innovator in Genetic Therapies
Introduction
Kenneth Loveday is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of genetic therapies, particularly in the treatment of α-galactosidase A deficiency. With a total of 5 patents to his name, his work has had a profound impact on medical science.
Latest Patents
Kenneth's latest patents focus on the treatment of α-galactosidase A deficiency. The inventions provide methods for treating this condition, including dosage forms, methods of administration, and techniques for analyzing human α-galactosidase A. These advancements are crucial for improving the quality of life for individuals affected by this deficiency.
Career Highlights
Throughout his career, Kenneth has worked with prominent companies in the pharmaceutical industry. He has been associated with Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited. His experience in these organizations has allowed him to develop innovative solutions in genetic therapies.
Collaborations
Kenneth has collaborated with esteemed colleagues such as Douglas A Treco and Marianne Borowski. These partnerships have contributed to the success of his projects and the advancement of genetic research.
Conclusion
Kenneth Loveday's contributions to the field of genetic therapies, particularly in treating α-galactosidase A deficiency, highlight his role as an influential inventor. His work continues to inspire advancements in medical science and improve patient outcomes.